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Abstract: Patients with mantle cell lymphoma (MCL) have a poor prognosis; consequently, 
new therapeutic approaches, such as rapamycin and its derivates, mammalian target of 
rapamycin (mTOR) inhibitors, are warranted. Temsirolimus (also known as CCI-779), a 
dihydroester of rapamycin, in MCL cell lines inhibited mTOR, downregulated p21 and v-Raf, 
and induced autophagy.The first clinical trial in MCL patients was performed using 250 mg 
of temsirolimus weekly for 6–12 cycles. The overall response rate was 38%; the median 
time to progression was 6.5 months, median overall survival was 12 months, and the median 
duration of response was 6.9 months. At lower dose (25 mg/week), the overall response rate 
was 41%, median overall survival was 14 months, and time to progression was 6 months. 
In another trial, 162 patients were randomly assigned to receive temsirolimus at 2 different 
doses (175 mg/week for 3 weeks, then 75 mg or 25 mg/week) or a treatment chosen by the 
investigator among the most frequently adopted single agents for treatment of relapsed MCL. 
Patients treated with 175/75 mg of temsirolimus had significantly higher response rates and 
longer progression-free survival than those treated with investigator’s choice therapy. These data 
support the use of mTOR inhibitors for the treatment of MCL, probably in combination with 
other agents, such as antiangiogenic drugs or histone acetylase inhibitors.
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Mantle cell lymphoma
Mantle cell lymphoma (MCL), which accounts for approximately 6% of all non-
Hodgkin lymphomas, represents the subtype where mammalian target of rapamycin 
(mTOR) inhibitors appear as more promising compounds in its treatment. The interest 
in application of these drugs to treat MCL has grown as it has been demonstrated that 
cyclin D1, overexpressed in this histotype of lymphoma, is an important downstream 
target of the mTOR signaling pathway.
Nevertheless, it has been reported that mTOR inhibitors inactivate other genes 
associated with the pathogenesis of MCL, such as vascular endothelial growth factor 
(VEGF), Ras, Raf, extracellular regulated kinase (ERK), and nuclear factor-kappa B. 
Moreover, the interest in this class of compounds has increased as more effective thera-
peutic strategies are required for MCL treatment, which has been demonstrated by the 
low response and survival rates observed in MCL patients treated with this drug.
Indeed, notwithstanding the most recent and effective therapeutic approaches 
adopted, the clinical evolution of most patients with MCL is still aggressive, with 
median overall survival not exceeding 3–4 years.1 Given the poor complete remission 
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investigated to improve the outcomes: one of these regi-
mens is the hyper-CVAD (fractionated cyclophosphamide, 
vincristine, doxorubicin, dexamethasone, alternating with 
high-doses methotrexate and cytarabine). This regimen, asso-
ciated with the anti-CD20 monoclonal antibody rituximab, 
has shown good efficacy and tolerability in MCL, offering 
high response rates and 3-year failure-free survival and 
overall survival of 64% and 82%, respectively.2 Analogously, 
rituximab combined with cyclophosphamide, adriamycin, 
vincristine and prednisone (R-CHOP) has been shown to be 
significantly superior to CHOP in overall response rate (94% 
vs 75%) and time to treatment failure (21 vs 14 months), 
with acceptable toxicity.3 In conclusion, the responses to 
second-line treatments of about 30% of patients affected by 
MCL relapse are still not fully satisfactory: rituximab associ-
ated with fludarabine, cyclophosphamide, and mitoxantrone 
(R-FCM) offered only 29% of complete remission;4 radioim-
munotherapy resulted in 30% of complete responses, with 
median event-free survival of 6 months and median overall 
survival of 21 months.5 Moreover, an objective response 
was achieved in 45% of patients receiving bortezomib, with 
median progression-free survival of only 6 months.6 Fifty-
three percent of patients responded well to lenalidomide, with 
a median duration of response of 13.7 months and median 
progression-free survival of 5.6 months.7,8
Targeting mTOR pathway
In the mid-1970s, a strain of Streptomyces hygroscopicus, 
producing a compound with potent antifungal activity, was 
isolated from the soil samples collected from the Rapa Nui 
Island in the South Pacific.9 From the geographical origin, the 
purified antibiotic was named “rapamycin.”10 In addition to 
antifungal activity, rapamycin was found to inhibit immune 
responses in mammals by depressing lymphocyte prolifera-
tion and to exert a cytostatic activity in several in vitro and in 
vivo cancer models.11 In the 1990s, rapamycin was found to 
exert its activities by an evolutionarily conserved pathway that 
integrates signals from growth factors, nutrients, and energy 
status. The activation of mTOR pathway signifies a decision 
point that takes into account the availability of materials 
required for cell growth (amino acids, glucose, and energy) 
and the growth-regulating signals (hormones and growth 
factors). Thus, the cells are protected from outside signals to 
grow and still proliferate when nutrients and energy inside 
are not sufficient (Figure 1).12
The human MTOR gene (GeneID: 2475) maps to chro-
mosome 1p36.2 and encodes a 289-kDa protein containing 
a kinase catalytic domain, 20 HEAT (Huntington elongation 
factor 1A-protein phosphatase) repeats, an autoinhibitory 
  repressor domain, and the FRB domain, responsible for 
interaction with FKBP12, a cofactor and transporter for 
rapamycin.13,14
The mTOR protein participates in 2 signaling complexes: 
mTORC1 and mTORC2. mTORC1, which is sensitive to 
rapamycin, includes mTOR, Raptor (regulatory-associated-
protein of mTOR), and GβL (G protein β-subunit-like 
protein). This complex reacts with signals that originate 
from growth factors, energy status, nutrient availability, 
hypoxia, reactive oxygen species, deoxyribonucleic acid 
(DNA) damage, and osmotic condition of environment.15 
mTORC1 is activated by numerous upstream signalling 
pathways, including PI3K/Akt, Ras/MAPK, and Bcr-Abl1, 
whereas the negative regulators are phosphatase and tensin 
homolog (PTEN), LKB1, and the heterodimer TSC1 (tuber-
ous sclerosis complex 1 or amartin)/TSC2 (tuberous sclerosis 
complex 2 or tuberin)16 (Figure 2). Activated Akt17 and Ras-
Raf-ERK pathways phosphorylate TSC1/TSC2, leaving the 
Rheb protein GTP-bound and capable of interacting with 
and activating mTOR.18
The activity of PI3K is countered by PTEN; loss of PTEN 
has been reported in several solid tumors and   lymphomas and 
seems to correlate with sensitivity to rapamycin derivatives.19
mTORC2 complex, rapamycin insensitive, contains 
mTOR, GβL, Rictor (rapamycin-independent companion 
of mTOR), and mSIN1 (mammalian stress-activated protein 
kinase interacting protein 1).20 It is believed that various 
growth factors contribute to mTORC2 activation. This com-
plex regulates cytoskeleton organization and activates Akt, 
thus representing a further important level of self-regulation 
of the mTOR pathway.21
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Figure 1 mTOR as central regulator of the cell nutrition and growth. Conditions 
outside of the cell, such as nutrient and energy levels, growth factors, hormones, 
and stressful conditions, control the mTOR activation. After activation, mTOR 
stimulates  cell  growth,  increases  angiogenesis,  and  responds  to  bioenergetics 
necessities.Cancer Management and Research 2010:2 submit your manuscript | www.dovepress.com
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Upon activation, mTOR facilitates cell cycle progression 
from G1 to S phase by phosphorylation of p70S6 kinase 
(p70S6K) and 4E-binding protein 1 (4E-BP1). p70S6K phos-
phorylates and activates S6, a ribosomal subunit involved in 
initiating translation of 5′ terminal oligopyrimidine tract-con-
taining mRNA encoding components of the protein synthesis 
machinery. The mTOR-mediated phosphorylation of 4E-BP1 
diminishes the stability of the 4E-BP1/eIF4E complex and 
facilitates the eIF4E action, enhancing translation of several 
mRNAs, such as cyclin D1, c-myc, hypoxia-inducible fac-
tor 1α (HIF1α), ornithine decarboxylase, VEGF, fibroblast 
growth factor, and   ribosomal proteins (Figure 3).22,23
mTOR inhibitors in hematological 
malignancies
Rapamycin (sirolimus) was the first mTOR inhibitor used in 
clinical practice;24 more recently, several rapamycin analogs 
have been tested in clinical trials for solid and hematological 
malignancies: temsirolimus (CCI-779; Wyeth Pharmaceu-
ticals, Madison, New Jersey, USA), everolimus (RAD001; 
Novartis, Basel, Switzerland), and deforolimus (MK-8669, 
AP23573; Merck and Ariad Pharmaceuticals, Cambridge, 
Massachusetts, USA).
Because mTOR is important for cell proliferation in several 
hematological malignancies, mTOR inhibitors have been used 
either as single drugs or in combination with conventional 
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Figure 2 mTOR upstream pathway. Amino acid, glucose levels, growth factors, and genes, such as Bcr-Abl and Ras, induce activation of the PI3K/Akt pathway and 
consequently of the mTOR. The Akt pathway is inhibited by PTEN and LKB1 through the TSC1–TSC2 complex.
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Figure 3 mTOR downstream pathway. mTOR activates the kinase activity of S6K1 
and mediates the release of eIF4E translation initiating factor, thus regulating the 
synthesis of proteins involved in growth, proliferation, survival, angiogenesis, and 
bioenergetics.
chemotherapeutic agents or monoclonal antibodies in acute/
chronic lymphocytic or myeloid leukemia, multiple myeloma, 
myelodysplastic syndromes, and lymphomas. mTOR 
inhibitors have been shown to be also effective against acute 
  lymphoblastic leukemia, even when combined with methotrex-
ate, anthracyclines, etoposide, or corticosteroids.24–27
Rapamycin restored sensitivity to steroid-resistant cells28 
and to tyrosine kinase inhibitors in resistant patients with Cancer Management and Research 2010:2 submit your manuscript | www.dovepress.com
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chronic myeloid leukemia.29 In acute myeloid leukemia, 
where Akt is activated, phosphorylation of p70S6K and 
4EBP-1 is significantly inhibited by everolimus, especially 
when combined with Ara-C.30 Also in myelodysplastic syn-
dromes, activation of the Akt/mTOR pathway in high-risk 
patients was described.31
The PI3K/Akt pathway is frequently activated in multiple 
myeloma, where mTOR inhibitors were effective.32,33 In a 
phase II trial, 16 patients with relapsed refractory multiple 
myeloma received 25 mg of intravenous temsirolimus weekly 
until progression, with overall response rate of 38% and 
median time to progression of 138 days.34
In Hodgkin’s lymphoma, everolimus downregulated the 
truncated isoform of the transcription factor CCAAT enhancer 
binding protein beta, which inhibits NF-kB activity.35 
Rapamycin has been shown to inhibit mTORC1 also in dif-
fuse large B-cell lymphoma cell lines36 and to overcome the 
P-glycoprotein-mediated multidrug resistance in B-lymphoma 
cell lines.37 In primary effusion lymphoma, rapamycin reduced 
the accumulation of ascites and extended mouse survival, with 
significant reduction in levels of circulating VEGF.38
Moreover, rapamycin showed a strong antiproliferative 
effect on B-cell lines derived from organ transplant recipients 
with Epstein–Barr virus-associated post-transplant lymphop-
roliferative disorders.39
mTOR inhibitors were effective in follicular lymphoma, 
where neoplastic cells display phosphorylation of p70S6K 
and 4E-BP1.40,41
In chronic lymphocytic leukemia (CLL) cells, where PI3K 
is constitutively active,42 cycle arrest induced by rapamycin 
was accompanied by reduced expression of cyclins D3, A, and 
E.43 A phase II trial with oral everolimus was conducted in 
7 patients with CLL relapsed after at least 2 lines of therapy. 
Disease stabilization was observed in 3 patients and partial 
response in 1 patient; however, the trial was precociously 
stopped because of infectious toxicity.44
MCL and mTOR inhibitors
Overexpression of the cyclin D1, product of the oncogene 
Bcl-1, is considered the primary genetic event in MCL and 
hence mTOR inhibitors are used in the treatment of MCL. 
Cyclin D1 plays a critical role in cell transition from the G to S 
phase in response to mitogens.45 The overexpression of cyclin 
D1 is due to the translocation t(11;14)(q13;q32) juxtaposing the 
Bcl-1 (CCND1) gene on chromosome 11 to the immunoglob-
ulin heavy chain locus (IgVH) on chromosome 14.46 t(11;14)
(q13;q32) is identified in 50%–70% of MCL cases based on 
the type of the method used.
Cyclin D1, in association with cyclin-dependent kinase-4 
and -6, induces the cell to enter the S phase by phosphory-
lating the retinoblastoma tumor-suppressing protein, which 
binds to transcription factors, including E2F.47
In addition to the overexpression of cyclin D1, other genes 
that overexpress in MCL, such as VEGF and Raf-1, represent 
further possible targets for mTOR inhibitors.
Indeed, a constitutive activation of Akt and mTOR 
pathways either in MCL cell lines (Granta 519, Jeko-1, and 
SP-53) or in primary cultures from 30% of MCL patients has 
been reported.48,49 Moreover, mTOR inhibitors in MCL could 
synergize with other “canonical” agents, such as vincristine, 
doxorubicin, bortezomib, and rituximab, with resulting inhi-
bition of Raf-1, MAPK, and mTOR.50,51
Nevertheless, the data on the in vitro activity of   different 
mTOR inhibitors in MCL cell lines are conflicting;52 
all   compounds induced cell cycle arrest in G0/G1 phase, 
  temsirolimus reduced p21 expression, and rapamycin 
increased p27 expression; however, the data on cyclin D1 
levels are still not clear (Table 1).
 In several MCL cell lines, pharmacological inhibition 
of the PI3K/Akt pathway by rapamycin was associated with 
downregulation of cyclin D1 and the antiapoptotic proteins 
cFLIP, Bcl-XL, and Mcl-1.53 Treatment with rapamycin 
inhibited the proliferation of Granta and NCEB cells, with 
accumulation of cells in G1 phase, without modification of 
the apoptotic process. The expression of cyclins D3, E, and 
A was strongly reduced in both cell lines, while cyclin D1 
expression was not changed.54,55
In another in vitro study, rapamycin inhibited cell prolif-
eration and induced cell cycle arrest in G0/G1 phase mediated 
by cyclin D3 and p27 deregulation. In the SP-53 cell line 
Table 1 In vitro activity of mTOR inhibitors on MCL cell lines: relevant data from literature
Drug Antiproliferative effect p27 Akt Cyclin D1 Cyclin D3 Reference
Rapamycin G0/G1 arrest Increased No change decreased No change Decreased Dal Col et al48
Rapamycin G0/G1 arrest Decreased Peponi53
Rapamycin G0/G1 arrest No change No change Decreased Hipp et al54
Temsirolimus Decreased Younes52
Temsirolimus G0/G1 arrest autophagy No change Increased No change No change Yazbeck et al57
Everolimus G0/G1 arrest Haritunians et al50Cancer Management and Research 2010:2 submit your manuscript | www.dovepress.com
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only, rapamycin downregulated cyclin D1 levels; this effect 
on cyclin D1 was observed only in cell lines where GSK3β 
was activated.48
In MCL, GSK3β is inactivated in about half the cases as a 
consequence of Wnt stimulation. After that, β-catenin is released 
and translocated into the nucleus, where it upregulates the tran-
scription of several genes, including cyclin D1.56
In MCL cell lines, cyclin D1 was unmodified by 
temsirolimus,57 which downregulated p21, thus inducing 
a cell cycle block in the G1 phase and exerting a cytostatic 
rather than a cytotoxic action.
Interestingly, temsirolimus showed a synergistic anti-
neoplastic activity with vorinostat, probably adding to the 
proapoptotic effect exerted by the histone acetylase inhibitors, 
the induction of autophagy. Autophagy is a reversible, bidirec-
tional process; it not only can enhance and promote survival 
under stressful conditions but also can lead to cell death. In 
an in vitro study on MCL cell lines, temsirolimus inhibited 
mTOR, downregulated p21, and induced autophagy without 
any effect on pERK, Bcl-2, Bax, Bad, and beclin-1.52
Another factor that supports the use of mTOR inhibitors 
in MCL is the inhibition of angiogenesis. Indeed, TORC1 
activation results in upregulation of HIF1α that leads to 
increased expression of angiogenic factors, such as VEGF 
and platelet-derived growth factor-β58 In well-oxygenated 
cells, HIF1α is continuously produced and degraded by prote-
osomes. In hypoxic cells, HIF1α translocates to the nucleus, 
initiating the transcription of genes involved in glycolysis, 
angiogenesis, cell survival, and metastasis. As VEGF is one 
of the regulators of the PI3K/Akt activity, increased levels 
of VEGF induce a further activation of mTOR. Inhibition of 
mTOR activity affects angiogenesis by reducing the expres-
sion of HIF1α . and by inhibiting the ability of cells to respond 
to the mitogenic effect of VEGF.
High levels of VEGF have been associated with poor 
outcomes in acute lymphoblastic leukemia59 and non-
Hodgkin lymphomas.60,61 In MCL, VEGF expression has 
been reported in 41% of cases, with an evident negative 
prognostic significance.62
Recently, our group showed that 2 VEGF polymorphisms 
associated with higher plasmatic protein levels, G+405C and 
C+936T, were more frequently detected in MCL cases than 
in healthy controls, thus supporting the hypothesis that some 
VEGF genotypes would increase the risk of development of 
this lymphoma.63
Another upstream regulator of mTOR, particularly inter-
esting in MCL, is the Ras/Raf/ERK/MAPK pathway.64 v-Raf 
has been reported to act synergistically with c-Myc to induce 
B-cell tumors in a murine model.65 In a series of patients with 
MCL and receiving R-hyper-CVAD, our group previously 
reported that c-Myc overexpression was associated with 
shorter overall and progression-free survival.66 Like c-Myc, 
Mcl-1 is overexpressed in MCL;67 this gene, a member of the 
bcl-2 family, is translationally regulated by mTORC1 and is 
involved in the antiapoptotic action of mTOR.68
Syk, a tyrosine kinase involved in B-cell receptor signal-
ling, has been reported to be amplified at the DNA level and 
overexpressed at both RNA and protein levels in MCL cell 
lines and in a small subset of clinical samples. As inhibition 
of Syk resulted in potent inhibition of mTOR activity in fol-
licular cells, mantle cells, Burkitt, and diffuse large B-cell 
lymphoma cell lines, this tyrosine kinase would represent a 
further good target for mTOR inhibitors.69
Temsirolimus for relapsed MCL
Temsirolimus (also known as CCI-779), a dihydroester of 
rapamycin suitable for intravenous use, is currently under 
trial for use in solid tumors, such as renal cancer,70 breast 
cancer,71 sarcomas,72 and prostate cancer.73 In hematology, 
it has been tested in MCL, multiple myeloma, and acute 
myeloid leukemia.74
The prototype mTOR inhibitor, oral rapamycin, is poorly 
soluble and undergoes extensive first-pass metabolism, lead-
ing to low and potentially variable absorption and exposure. 
Table 2 Temsirolimus in MCL patients: results from clinical trials
Schedule No. of  
patients
Overall  
response
Complete  
response
Median overall  
survival
Median  
progression- 
free survival
Reference
Temsirolimus 250 mg/wk 35 38% 3% 12 mo 6.5 mo Witzig et al76
Temsirolimus 25 mg/wk 29 41% 3.7% 14 mo 6 mo Ansell et al78
Temsirolimus 175-75 vs  
175–25 vs chosen therapy
162 22% vs  
6% vs 2%
11.1 mo vs  
8.8 mo vs  
9.5 mo
7.4 mo vs  
3.4 mo vs  
1.6 mo
Hess et al79
Temsirolimus 25 mg/wk +  
rituximab 4×
71 48% 20% 9.5 mo Ansell et al81Cancer Management and Research 2010:2 submit your manuscript | www.dovepress.com
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For some tumors, maximizing the bioavailability and dose 
intensity via intravenous administration may provide optimal 
clinical benefit. Temsirolimus is an ester analog of rapamycin 
that retains its potent intrinsic mTOR inhibitory activity while 
exhibiting better solubility for intravenous formulation. In the 
treatment of advanced renal cell carcinoma, temsirolimus is 
administered as a 30- to 60-minute infusion once weekly at a flat 
dose of 25 mg. This dosage results in high peak temsirolimus 
concentrations and limited immunosuppressive activity.75
From April 2002 to October 2003, 35 MCL patients 
(median age of 70 years, 91% in stage IV) who failed therapies 
with alkylating agents, cyclophosphamide, anthracyclines, 
purine analogs, and rituximab received 250 mg of temsirolimus 
weekly for 6–12 cycles76 (Table 2). The overall response rate 
was 38%, with 3% of complete remissions and 35% of partial 
responses achieved by 3 months. The median time to progres-
sion was 6.5 months, median overall survival was 12 months, 
and the median duration of response was 6.9 months. Nev-
ertheless, dose reduction was necessary in 31 cases: 71% of 
patients experienced grade 3 and 9% experienced grade 4 
hematological toxicity. Thrombocytopenia, anemia, neutrope-
nia, increased triglycerides, diarrhea, hyperglycemia, sensory 
neuropathy, and rash were the most frequent adverse events.
The most frequent toxicities reported for mTOR inhibitors 
are mucositis, stomatitis, pneumonitis, rash, nail dystrophy, 
hyperlipidemia, hyperglycemia, and bone marrow suppres-
sion. In phase II trials in renal and breast cancer, the overall 
favorable safety profile of temsirolimus was confirmed; 
grade 3–4 mucositis was observed in ,5%, skin rash in 4%, 
pneumonitis in 5%, hyperlipidemia in 6%, hyperglycemia 
in 17%, thrombocytopenia in ,5%, and anemia in 9% of 
treated patients.77 Thrombocytopenia grade 3–4 occurred in 
65%, anemia in 25%, and neutropenia in 28% of MCL cases; 
this difference was probably due to the frequent involvement 
of bone marrow (91% of patients were in stage IV) and 
treatments previously received. Nevertheless, only 1 patient 
required platelet transfusion and 4 required red cells support. 
The lower dose levels were evaluated in a phase II trial by 
the North Central Cancer Treatment Group.78
The objective of this study was to test a low dose of 
temsirolimus (25 mg weekly) in patients with relapsed 
MCL. Patients who had a tumor response after 6 cycles 
were eligible to continue the drug for a total of 12 cycles 
or 2 cycles after complete remission. The median age of 
the 29 enrolled patients was 69 years, with 86% of patients 
in stage IV . The overall response rate was 41%, with 37% 
of partial responses. The median overall survival from the 
study entry was 14 months, and the time to progression and 
median duration of response were 6 months. Hematological 
toxicities were the most common toxicities, with 50% grade 
3 and 4% grade 4 adverse events. Thrombocytopenia was 
the most frequent cause of dose reduction. Three patients 
experienced infection without concomitant neutropenia. 
Thus, this trial reported responses similar to those described 
for higher dose, but with less toxicity.
From June 2005 to July 2007, 162 patients were randomly 
assigned to receive temsirolimus at 2 doses (175 mg/wk for 3 
weeks and then 75 mg or 25 mg/week) or a treatment chosen 
by the single investigator among the most frequently adopted 
agents for the treatment of relapsed MCL (gemcitabine, 
fludarabine, chlorambucil, cladribine, etoposide, thalido-
mide, vinblastine, alemtuzumab, lenalidomide).79 Median 
progression-free survival was 4.8, 3.4, and 1.9 months for 
temsirolimus 175/75 mg, temsirolimus 175/25 mg, and inves-
tigator’s choice groups, respectively. Patients treated with 
temsirolimus 175/75 mg had significantly longer progression-
free survival than those treated with investigator’s choice 
therapy; those treated with temsirolimus 175/25 mg showed 
a trend toward longer progression-free survival. The objec-
tive response rate was significantly higher in the 175/75 mg 
group (22%) than in the investigator’s choice group (2%). The 
median overall survival for the temsirolimus 175/75 mg group 
and the investigator’s choice group was 12.8 and 9.7 months, 
respectively. The advantage offered by temsirolimus was inde-
pendent of age, sex, performance status, stage of disease at 
diagnosis, number of extranodal sites, and blastoid histology. 
The most frequent grade 3 or 4 adverse events documented 
in 89% of patients in the temsirolimus 175/75 mg group 
and in 80% of patients in the temsirolimus 175/25 group 
were thrombocytopenia, anemia, neutropenia, and asthenia. 
Grade 3/4 thrombocytopenia was higher in the temsirolimus 
175/75 mg group (59% vs 36% in the investigator’s choice 
arm), anemia was comparable in the 2 arms (20% vs 17%), 
and neutropenia was lower in temsirolimus group (15% vs 
26%). In the group of patients treated with temsirolimus, 
the most frequent side effects were asthenia (13% vs 8%), 
infection (9% vs 4%), diarrhea (7% vs 0%), rash (7% vs 0%), 
dyspnea (7% vs 9%), fever (6% vs 0%), and pruritus (4% vs 
0%). Nevertheless, a lower number of patients discontinued 
treatment with temsirolimus compared with those receiving 
standard therapies (43% vs 52%), maintaining also a good 
quality of life.
At the 2009 European Hematology Association meet-
ing, results from this trial were updated. The median 
  progression-free survival and overall survival w  ere 
  confirmed to be significantly longer for the patients treated Cancer Management and Research 2010:2 submit your manuscript | www.dovepress.com
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with 175/75 mg temsirolimus than for those treated with 
investigator’s choice therapy (5.2 vs 1.9 months and 5.2 vs 
2 months, respectively).80
Moreover, considering the ability of rituximab to inhibit 
Akt and Raf-1 signalling pathways, 71 relapsed/resistant MCL 
patients received 25 mg of intravenous temsirolimus every 
week and 4 weekly doses of rituximab in the first cycle, and 
then 1 dose of rituximab every other cycle, between May 2005 
and March 2009.81 Patients with a tumor response after 6 cycles 
were eligible to continue treatment for a total of 12 cycles or 
2 cycles after complete remission, and were then observed 
without maintenance. With median age of 67 years, 28% of 
patients were rituximab refractory. The overall response rate 
was 48%, with 20% of complete and 28% of partial responses. 
The median duration of response was 9.5 months for rituximab-
sensitive patients and 7.15 months for rituximab-refractory 
patients. While the combination was generally well tolerated, 
12 patients experienced grade 4 toxicity. Hematological 
toxicities were most common, with 5 patients having grade 4 
thrombocytopenia and 3 having grade 4 neutropenia.
Responses (30%) to temsirolimus by patients with MCL 
are higher than those reported by patients with renal cell 
carcinoma, breast cancer, lung cancer, and glioblastoma 
(about 10%). Why patients affected by lymphoma would 
be more sensitive than those affected by solid tumors is still 
unexplained; some authors suggest that the different ways 
of inactivation of PTEN (phosphorylation in lymphoma and 
mutation/deletion in solid tumors) could be one possible 
cause. It is also possible that prolonged exposure to temsi-
rolimus could inactivate both the mTORC1 and mTORC2 
complexes in sensitive tumors, therefore inhibiting the nega-
tive feedback of phosphorylation of Akt.53
Considering these promising results, the future perspective 
would be to test other mTOR inhibitors , such as everolimus, 
or drug combinations in MCL, but as first-line therapies.As 
reported in the 2009 American Society of Hematology meet-
ing, 37 patients with relapsed diffuse large cell lymphoma and 
MCL received 5 mg/day of everolimus. The overall response 
rate was 32%, with 29% in the MCL group. The median time 
to progression for all patients was 3.1 months. The median 
duration of response for the 12 responders was 5.5 months. 
Everolimus was well tolerated, with the incidence of grade 
3 anemia, neutropenia, and thrombocytopenia occurring in 
11%, 16%, and 30% of cases.82
Thus, the perspective of using mTOR inhibitors as first-line 
treatment for MCL patients would be a challenge for the next 
future; the association of rituximab, cladribine, and temsiroli-
mus is scheduled for the newly diagnosed MCL (registered at 
ClinicalTrials.gov as NCT00787969, April 2009). This phase 
I/II trial is planned to evaluate the efficacy and safety of tem-
sirolimus when given together with cladribine and rituximab; 
the treatment is repeated every 28 days for up to 6 courses in 
the absence of disease progression or unacceptable toxicity. 
As secondary endpoints, the trial includes the assessment of 
metabolic markers (hyperglycemia and hyperlipidemia) as 
markers of mTOR inhibition and correlation of response with 
serum-free light chains, single-nucleotide polymorphisms in 
host immune genes, vitamin D metabolites, and PI3K pathway 
member expression.
It is probable that patients not heavily pretreated could 
represent the best scenario for using mTOR inhibitors to 
reduce toxicities and increase their efficacies.
In conclusion, the demonstration that temsirolimus at 
175 mg/week as induction, followed by 75 mg/week, signifi-
cantly improved clinical benefit (response rate and progression-
free survival) in comparison to “canonical” drugs is the most 
convincing element for considering the use of this mTOR 
inhibitor in relapsed MCL patients. Moreover, the fact that 
temsirolimus is well tolerated in general and that severe clinical 
side effects .grade 3 are rare events represents another sup-
porting element. Obviously, the optimal dose of temsirolimus, 
as well as the exploration of new combinations (in particular 
with anti-CD20 antibodies, histone deacetylase inhibitors and 
inhibitors of Raf or angiogenesis), is still under discussion, and 
further studies enrolling larger series of patients are warranted 
to confirm the above reported promising clinical results.
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